Heron Therapeutics Q1 Earnings Call Highlights
Key takeaways
- Heron Therapeutics Q1 Earnings Call Highlights Market Beat Mon, May 11, 2026 at 10:07 PM GMT+7 6 min read HRTX Heron Therapeutics logo Key Points Interested in Heron Therapeutics, Inc.?
- Heron reaffirmed its full-year 2026 outlook despite a weak first quarter, with net product sales of $34.7 million and adjusted EBITDA of negative $727,000.
- Acute care products drove growth, with the portfolio up 32% year over year.
Heron Therapeutics Q1 Earnings Call Highlights Market Beat Mon, May 11, 2026 at 10:07 PM GMT+7 6 min read HRTX Heron Therapeutics logo Key Points Interested in Heron Therapeutics, Inc.? Here are five stocks we like better.
Heron reaffirmed its full-year 2026 outlook despite a weak first quarter, with net product sales of $34.7 million and adjusted EBITDA of negative $727,000. Management said seasonal issues, winter weather, and temporary supplier-related margin pressure were the main drags, and expects conditions to improve through the year.
Acute care products drove growth, with the portfolio up 32% year over year. ZYNRELEF and APONVIE both posted strong demand gains, helped by improving reimbursement dynamics, expanded account coverage, and the rollout of Heron’s Ignite incentive program.